- Drugs
- Friday, 20 Sep 2019
Aurora Cannabis and UFC Launch Clinical Research on Use of Hemp-Derived CBD Products by MMA Athletes
Aurora Cannabis Inc. and UFC, the world's premier mixed martial arts organization, announced the launch of a joint clinical research program that will produce multiple studies under the terms of their recently announced partnership. Aurora Cannabis Inc. the Canadian company defining the future of cannabis worldwide, announced that it has received Health Canada licenses for outdoor cultivation at two Canadian sites.
Aurora Cannabis Inc. and EnWave Corporation entered into a royalty-bearing commercial license agreement providing Aurora with the exclusive rights to EnWave's patented Radiant Energy Vacuum (REVTM) drying technology for the production of cannabis materials in the European Union, excluding Portugal.
Aurora Cannabis, Inc. is a Canada-based company, which is engaged in the production and distribution of medical cannabis. It also produces and sells indoor cultivation systems and hemp related food products. Through state-of-the-art production facilities and exclusive sales agreements in the European Union and beyond, the company operates around the globe pursuing new and emerging cannabis markets. The company was founded by Terry Booth and Steve Dobler on December 21, 2006 and is headquartered in Edmonton, Canada.
Aurora Cannabis is expanding its network of subsidiaries and partnerships that offers strategic differentiation through its broad global reach, high-tech, low-cost production facilities, unique product offerings and science driven innovations across the entire cannabis value chain. Aurora is rapidly developing its assets and capabilities in the emerging CBD-based wellness market. With extensive hemp assets across Canada, Latin America and Europe, combined with an industry-leading product development team and deep brand building capabilities, the Company is well positioned to pursue a leading role in this rapidly developing segment.
Related Industry Updates
Sickle Cell Disease Treatment Market is expected to reach US$ 4,691.87 million by 2030
Nov 07, 2023
Alkermes Completes Avadel Deal, Expands Sleep Medicine Market Reach
Feb 13, 2026
Zongertinib Gets Accelerated FDA Nod for HER2 NSCLC
Aug 14, 2025
Emerging nations represent an excellent opportunity for the pharmaceutical industry to develop anti-fungal drugs
Sep 24, 2019
Johnson & Johnson Announces Collaboration with U.S. Department of Health & Human Services to Accelerate Development of a Potential Novel Coronavirus Vaccine
Feb 13, 2020
Glioma Treatment Market is expected to reach US$ 8,291.3 million by 2030
Sep 18, 2023
Sterilization Technologies Market is expected to reach US$ 9,109.08 million by 2030
Feb 16, 2024